Amylyx Pharmaceuticals, Inc. (AMLX)

NASDAQ • Healthcare

$27.2

-$1.37 (-4.8%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$28.46

Previous Close$27.2

Day Range$27.06 - $28.46

Avg. Volume (3M)1.3M

Market Cap$3.4B

52 Week Range

$10.83$41.14

Next EarningsIn 11 daysNov 5, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)

Net Income (TTM)

-$152M

EPS (TTM)

-$1.41

ROA (TTM)

-57.49%

Current Ratio

12.12

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-4.5%Q3 2025-$0.46

+14.0%Q4 2025-$0.37

+3.2%Q1 2026-$0.3

-8.8%Q2 2026-$0.37

-8.1%Q3 2026-$0.39

Nov 5

in 11 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -8.1%

Amylyx Pharmaceuticals’ earnings missed consensus in the second fiscal quarter of 2026, based on preliminary results reported August 6, 2026, with EPS of -$0.39 trailing the -$0.36 estimate by -$0.03. The company posted GAAP net income of roughly -$43.4 million, down about 5% year over year from -$41.4 million a year ago, while GAAP operating income was around -$45.7 million. Cash flow from operations was negative at roughly -$31.4 million for the quarter. Amylyx remains a clinical-stage biopharmaceutical company focused on AMX0035 in amyotrophic lateral sclerosis and other neurodegenerative conditions. For the next period, consensus calls for EPS of -$0.38 on revenue of $59,429.00.

Next report — what to expect

Amylyx Pharmaceuticals, Inc. (AMLX) is scheduled to report earnings on November 5, 2026. Wall Street’s next-period consensus calls for EPS of -$0.383 on revenue of $59,429.00. In recent history, Amylyx has beaten EPS expectations in 3 of its 8 most recent quarters, so attention may center on whether results align with that baseline.

View full earnings history

About Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. is a NASDAQ-listed healthcare company in biotechnology that develops therapies for amyotrophic lateral sclerosis and other neurodegenerative conditions. The company operates as a clinical-stage biopharmaceutical firm, with its work centered on AMX0035, a named therapy candidate that anchors its development pipeline and research focus.

Name

Amylyx Pharmaceuticals, Inc.

CEO

Joshua Cohen

Website

amylyx.com

Industry

Healthcare

Year Founded

2013

Employees

136

Today's Snapshot

AI-generated

The day ended with AMLX 4.8% lower at 27.20, in line with a weaker sector. AMLX is due to report earnings on 5 November.

Trading Volume

Below 10d avg (1.2M)

1.1M

vs S&P 500 Today

Strong Underperformance

-4.28%

Updated: October 23, 2026 at 20:17 UTC

Technical Indicators

2 Buy3 Neutral3 Sell

Amlonix exhibits a weaker near-term technical profile, with price below several short- and medium-term moving averages and trading under the pivot near 29.03, which supports a bearish bias. Momentum has turned negative and MACD is not confirming strength, while ADX remains muted, implying the downtrend lacks strong conviction; volatility is higher than average and OBV readings favor distribution. Longer-term averages are higher, but they currently act as resistance rather than support. Technical takeaway: Sell — downside pressure below key short-term averages and declining volume underpin the bearish stance.

All signals

EMA (5 indicators)$21.40 - $28.38
Sell
RSI (14)42.70
Neutral
Stochastic %K (14, 3, 3)57.71
Neutral
MACD Level (12, 26)-0.65
Neutral

Peers & Related Assets

IONSIonis Pharmaceuticals, Inc.

$42.93-2.2%

PRAXPraxis Precision Medicines, Inc.

$252.96-2.3%

DNLIDenali Therapeutics Inc.

$18.41-1.3%

PRTAProthena Corporation plc

$8.2-0.6%

AVXLAnavex Life Sciences Corp.

$1.33-2.2%

ACIUAC Immune S.A.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.